ABBOTT AND THE FOOD AND DRUG ADMINISTRATION WERE ALERTED TO PROBLEMS WITH THE PRODUCTION OF INFANT FORMULA MONTHS EARLIER THAN BOTH THE COMPANY AND AGENCY HAD PREVIOUSLY ADMITTED.
A COMPLAINT WAS FILED WITH OSHA IN FEBRUARY OF 2021 BY A FORMER ABBOTT EMPLOYEE. THE COMPLAINT WAS SENT TO BOTH ABBOTT AND THE FDA.
THE COMPLAINT ALLEGED A SLEW OF PROBLEMS AT THE COMPANY’S STURGIS FACILITY INCLUDING FAILING EQUIPMENT AND FORMULA SENT TO MARKET WITHOUT ADEQUATE TESTING.
ABBOTT RESPONDED TO THE COMPLAINT TWO MONTHS LATER.
ANOTHER COMPLAINT WAS FILED IN OCTOBER OF 2021, BY THE SAME FORMER EMPLOYEE, MAKING SIMILAR ALLEGATIONS.
ABBOTT CLOSED ITS STURGIS FACILITY IN FEBRUARY OF THIS YEAR AS A RESULT.
BUT DURING A CONGRESSIONAL HEARING LAST MONTH, NEITHER THE FDA NOR ABBOTT ACKNOWLEDGED THE FEBRUARY 2021 COMPLAINT.
IN FACT, ABBOTT’S V.P. OF U.S. NUTRITION SAID THE COMPANY DIDN’T LEARN ABOUT THE COMPLAINT UNTIL IT WAS MADE PUBLIC BY CONGRESS THIS APRIL.
THE FDA SAID THE FIRST TIME IT HEARD OF THE COMPLAINT WAS FEBRUARY OF 2022.